Free Trial
The Rate Lock Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 a Year
Claim MarketBeat All Access Sale Promotion
NASDAQ:AUPH

Aurinia Pharmaceuticals Q3 2026 Earnings Results & Report

Aurinia Pharmaceuticals logo
$16.77 -0.44 (-2.55%)
As of 12:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Aurinia Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q3 2026 results, released October 30, 2026. The company reported EPS of $0.23 versus the $0.22 consensus estimate, while revenue of $83.70 million topped the $83.61 million estimate by $91.00 thousand.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
10:30 AM ET

Aurinia Pharmaceuticals EPS Results

Actual EPS
$0.23
Consensus EPS
$0.22
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Aurinia Pharmaceuticals Revenue Results

Actual Revenue
$83.70 million
Expected Revenue
$83.61 million
Beat/Miss
Beat by +$91.00 thousand
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Aurinia Pharmaceuticals' Q3 2026 Press ReleasePress Release
(6-K)
Aurinia Pharmaceuticals' Q3 2026 Quarterly reportQuarterly report
(10-Q)

Aurinia Pharmaceuticals Q3 2026 Earnings FAQ

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported earnings of $0.23 per share for Q3 2026, beating the consensus estimate of $0.22. The report was announced on Friday, October 30, 2026.

Aurinia Pharmaceuticals reported revenue of $83.70 million for Q3 2026, against a consensus estimate of $83.61 million.

Aurinia Pharmaceuticals Earnings Headlines

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
 |  financialpost.comF
Why Aurinia Pharmaceuticals (AUPH) is a top growth stock for the long term
October 26, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/why-aurinia-pharmaceuticals-auph-is-a-top-growth-stock-for-the-long-term/ar-AA2g67Ay
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
October 30 at 1:00 AM  |  Weiss Ratings (Ad)
Why Aurinia Pharmaceuticals (AUPH) is a top momentum stock for the long term
October 23, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/why-aurinia-pharmaceuticals-auph-is-a-top-momentum-stock-for-the-long-term/ar-AA2fUVHg
Aurinia Pharmaceuticals Inc (AUPH) - What Are Researchers Saying About This Stock?
October 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148291
AUPH - Aurinia Pharmaceuticals Inc.
October 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/AUPH
See More Aurinia Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aurinia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aurinia Pharmaceuticals and other key companies, straight to your email.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals (NASDAQ:AUPH). is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis. Aurinia’s activities include commercial operations, medical education, patient support, and ongoing research related to autoimmune and kidney diseases.

Aurinia was founded in Canada and has served patients and healthcare providers primarily in the United States, while also pursuing international commercial and development opportunities through partnerships. The company is headquartered in Victoria, British Columbia, and maintains operations supporting the development and commercialization of its therapies.

View Aurinia Pharmaceuticals Profile
Earnings Tools